Chemical Property of Lumiracoxib
Chemical Property:
- Appearance/Colour:Pale yellow solid
- Vapor Pressure:5.68E-07mmHg at 25°C
- Melting Point:139-141 °C
- Refractive Index:1.628
- Boiling Point:395.7 °C at 760 mmHg
- PKA:4.18±0.10(Predicted)
- Flash Point:193.1 °C
- PSA：49.33000
- Density:1.363 g/cm3
- LogP:4.23120
- Storage Temp.:-20°C Freezer
- Solubility.:≥29.4 mg/mL in DMSO; insoluble in H2O; ≥27.15 mg/mL in EtOH with ultrasonic
- XLogP3:4.2
- Hydrogen Bond Donor Count:2
- Hydrogen Bond Acceptor Count:4
- Rotatable Bond Count:4
- Exact Mass:293.0618845
- Heavy Atom Count:20
- Complexity:342
- Purity/Quality:
-
99% *data from raw suppliers
Lumiracoxib *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CC1=CC(=C(C=C1)NC2=C(C=CC=C2Cl)F)CC(=O)O
- Recent ClinicalTrials:Efficacy of Lumiracoxib in Relieving Moderate to Severe Post-dental Surgery Pain, Compared to Both Placebo and Celecoxib
- Recent EU Clinical Trials:A retrospective pharmacogenetic analysis of patients with elevated liver enzymes (Hy s law cases or AST/ALT > 10x ULN) in clinical studies CCOX189A0117, CCOX189A2332, CCOX189A2369, CCOX189A0126, CCOX189A0112, CCOX189A0109 or CCOX189A2361
-
Description
As a second-generation, selective cyclooxygenase (COX-2) inhibitor, lumiracoxib
is devoid of the gastrointestinal issues that plague other non-selective, nonsteroidal,
anti-inflammatory drugs (NSAIDs) that crossover to COX-1. As an inhibitor
of the inducible COX-2 that is up-regulated in pathological processes of
pain and inflammation, lumiracoxib blocks the conversion of arachidonic acid to
prostaglandins, the mediators of the pathological effects. It’s mode of binding to
COX-2 has been found to differ from the other selective COX-2 inhibitors; the
carboxylic acid forms hydrogen bonds with Tyr-385 and Ser-530 in the catalytic site
rather than seeking interactions within the larger hydrophobic side pocket. Since lumiracoxib is mainly metabolized by CYP2C9, a study evaluating
the co-administration of lumiracoxib with fluconazole, a potent inhibitor of
CYP2C9, was conducted, and it concluded that there was no need for lumiracoxib
dose adjustment, since changes in the systemic exposure were not significant. No
serious adverse effects were reported, but in the small number of cases where
treatment was discontinued, Gastro intestinal (GI) and musculoskeletal complaints
were common. Lumiracoxib is a selective inhibitor of COX-2 with IC50 values of 0.13 and 67 μM for COX-2 and COX-1, respectively, in isolated human whole blood. It reduces increases in the levels of prostaglandin E2 (PGE2; ) induced by IL-1β in human dermal fibroblasts (IC50 = 0.14 μM), as well as in LPS-stimulated RAW 264.7 cells when used at concentrations ranging from 1 to 100 μM., Lumiracoxib (3 and 10 mg/kg) also decreases LPS-induced increases in the levels of PGE2 in a rat model of air pouch inflammation. It reduces M. tuberculosis-induced increases in hind paw volume and the radiological and histopathological severity of arthritic lesions in a rat model of chronic arthritis when administered at a dose of 2 mg/kg.
-
Uses
Lumiracoxib is a selective cyclooxygenase-2-(COX-2) inhibitor and an anti-inflammatory agent (1,2,3,4). Selective cyclooxygenase-2-(COX-2) inhibitor. Anti-inflammatory. antiinflammatory, analgesic, antiarthritic
